Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

V Smith1, J T Van Praet, B Vandooren

  • 1Department of Rheumatology, Ghent University Hospital 0K12-IB, De Pintelaan 185, B-9000, Gent, Belgium. Vanessa.Smith@ugent.be

Annals of the Rheumatic Diseases
|December 24, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nailfold capillaroscopy and organ involvement in systemic sclerosis: a systematic review.

Best practice & research. Clinical rheumatology·2026
Same author

Capillaroscopy in the daily clinic of the pediatric rheumatologist.

Best practice & research. Clinical rheumatology·2024
Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken.

Acta clinica Belgica·2023
Same author

Reply: Artificial intelligence as a door opener for a new era of human reproduction.

Human reproduction open·2023
Same author

The development and acceptability of an educational and training intervention for recruiters to neonatal trials: the TRAIN project.

BMC medical research methodology·2023
Same journal

Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.

Annals of the rheumatic diseases·2026
Same journal

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same journal

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same journal

PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.

Annals of the rheumatic diseases·2026
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
See all related articles

Rituximab shows promise for diffuse cutaneous systemic sclerosis (dc-SSc) skin disease. This study found rituximab well-tolerated, effectively depleting B-cells and improving skin sclerosis scores.

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Diffuse cutaneous systemic sclerosis (dc-SSc) is a severe autoimmune condition characterized by skin thickening and potential organ damage.
  • Current treatments for dc-SSc have limitations, necessitating exploration of novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the safety and efficacy of rituximab in patients with diffuse cutaneous systemic sclerosis (dc-SSc).

Main Methods:

  • An open-label study involving eight dc-SSc patients treated with rituximab infusions at baseline and day 15.
  • Assessments included B-cell counts (CD19+), skin sclerosis scores, organ function indices, disability, and skin histopathology.

Main Results:

  • Rituximab effectively depleted peripheral B-cells in all patients.

Related Experiment Videos

  • Significant improvements were observed in skin sclerosis scores, dermal collagen content, and myofibroblast numbers.
  • Two serious adverse events were reported, deemed unrelated to rituximab.

    • Conclusions:

    • Rituximab appears to be a safe and potentially effective treatment for the skin manifestations of dc-SSc.